410 related articles for article (PubMed ID: 10870809)
1. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.
Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of lipoprotein lipase activity by tissue factor pathway inhibitor.
Mukherjee M; Kakkar VV
Thromb Haemost; 1999 Dec; 82(6):1648-51. PubMed ID: 10613650
[TBL] [Abstract][Full Text] [Related]
3. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
[TBL] [Abstract][Full Text] [Related]
4. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.
Gosk-Bierska I; Wysokin Ski W; Karnicki K; Adamiec R
Int Angiol; 2008 Aug; 27(4):296-301. PubMed ID: 18677291
[TBL] [Abstract][Full Text] [Related]
5. The present status of tissue factor pathway inhibitor.
Lindahl AK; Sandset PM; Abildgaard U
Blood Coagul Fibrinolysis; 1992 Aug; 3(4):439-49. PubMed ID: 1420819
[TBL] [Abstract][Full Text] [Related]
6. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity.
Salemink I; Franssen J; Willems GM; Hemker HC; Li A; Wun TC; Lindhout T
Thromb Haemost; 1998 Aug; 80(2):273-80. PubMed ID: 9716152
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.
Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H
Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212
[TBL] [Abstract][Full Text] [Related]
8. Structure and biology of tissue factor pathway inhibitor.
Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
[TBL] [Abstract][Full Text] [Related]
9. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man.
Hansen JB; Sandset PM; Huseby KR; Huseby NE; Nordøy A
Thromb Haemost; 1996 Nov; 76(5):703-9. PubMed ID: 8950777
[TBL] [Abstract][Full Text] [Related]
10. Effect of tissue factor pathway inhibitor (TFPI) in the HEPTEST assay and in an amidolytic anti factor Xa assay for LMW heparin.
Kristensen HI; Ostergaard PB; Nordfang O; Abildgaard U; Lindahl AK
Thromb Haemost; 1992 Sep; 68(3):310-4. PubMed ID: 1332210
[TBL] [Abstract][Full Text] [Related]
11. Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease.
Eling M; Stephens AC; Oragui EE; Rivers RP; Levin M
Thromb Haemost; 2001 Feb; 85(2):240-4. PubMed ID: 11246540
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.
Petersen LC; Sprecher CA; Foster DC; Blumberg H; Hamamoto T; Kisiel W
Biochemistry; 1996 Jan; 35(1):266-72. PubMed ID: 8555184
[TBL] [Abstract][Full Text] [Related]
13. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration.
Gori AM; Pepe G; Attanasio M; Falciani M; Abbate R; Prisco D; Fedi S; Giusti B; Brunelli T; Giusti B; Brunelli T; Comeglio P; Gensini GF; Neri Serneri GG
Thromb Haemost; 1999 Apr; 81(4):589-93. PubMed ID: 10235445
[TBL] [Abstract][Full Text] [Related]
14. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
Falciani M; Gori AM; Fedi S; Chiarugi L; Simonetti I; Dabizzi RP; Prisco D; Pepe G; Abbate R; Gensini GF; Neri Serneri GG
Thromb Haemost; 1998 Mar; 79(3):495-9. PubMed ID: 9531029
[TBL] [Abstract][Full Text] [Related]
15. Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation.
Adams M; Breckler L; Stevens P; Thom J; Baker R; Oostryck R
Haematologica; 2004 Aug; 89(8):985-90. PubMed ID: 15339683
[TBL] [Abstract][Full Text] [Related]
16. Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants.
Liestøl S; Sandset PM; Jacobsen EM; Mowinckel MC; Wisløff F
Br J Haematol; 2007 Jan; 136(1):131-7. PubMed ID: 17092306
[TBL] [Abstract][Full Text] [Related]
17. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation.
Shimura M; Wada H; Wakita Y; Nakase T; Hiyoyama K; Nagaya S; Mori Y; Shiku H
Am J Hematol; 1996 Jul; 52(3):165-70. PubMed ID: 8756081
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of behaviors of plasma tissue factor and tissue factor pathway inhibitor in patients with various diseases].
Saito M; Morishita E; Asakura H; Jokaji H; Uotani C; Kumabashiri I; Yamazaki M; Aoshima K; Matsuda T
Rinsho Ketsueki; 1996 Sep; 37(9):794-8. PubMed ID: 8914465
[TBL] [Abstract][Full Text] [Related]
19. [Value of plasma tissue factor, tissue factor pathway inhibitor and factor VII assessments in patients with acute myocardial and cerebral infarction].
Xiong SL; Wang Q; Zheng L; Li JL; Wen ZB; He SL
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Dec; 27(12):1821-3. PubMed ID: 18158992
[TBL] [Abstract][Full Text] [Related]
20. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins.
Valentin S; Nordfang O; Bregengård C; Wildgoose P
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):713-20. PubMed ID: 8292720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
